Lifesci Capital Weighs in on Immunovant Q2 Earnings

Immunovant, Inc. (NASDAQ:IMVT) – Research analysts at Lifesci Capital issued their Q2 2026 earnings estimates for shares of Immunovant in a research report issued on Monday, August 11th. Lifesci Capital analyst S. Slutsky anticipates that the company will earn ($0.70) per share for the quarter. The consensus estimate for Immunovant’s current full-year earnings is ($2.69) per share. Lifesci Capital also issued estimates for Immunovant’s Q3 2026 earnings at ($0.70) EPS, Q4 2026 earnings at ($0.70) EPS and FY2026 earnings at ($2.81) EPS.

Immunovant (NASDAQ:IMVT) last posted its earnings results on Monday, August 11th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.69) by $0.09. During the same quarter in the prior year, the firm posted ($0.60) EPS.

Several other equities analysts have also recently issued reports on the stock. The Goldman Sachs Group upgraded shares of Immunovant to a “hold” rating and set a $18.00 target price on the stock in a research note on Thursday, July 10th. Bank of America dropped their price objective on shares of Immunovant from $33.00 to $30.00 and set a “buy” rating on the stock in a report on Tuesday. Citigroup reaffirmed a “buy” rating on shares of Immunovant in a report on Monday. JPMorgan Chase & Co. reduced their target price on shares of Immunovant from $40.00 to $37.00 and set an “overweight” rating for the company in a report on Tuesday. Finally, UBS Group upped their target price on shares of Immunovant from $17.00 to $18.00 and gave the company a “neutral” rating in a report on Monday, July 28th. Three research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $35.20.

Immunovant Stock Performance

IMVT opened at $15.20 on Thursday. The stock has a market capitalization of $2.65 billion, a P/E ratio of -5.33 and a beta of 0.66. The company’s 50-day simple moving average is $16.53 and its two-hundred day simple moving average is $16.98. Immunovant has a 52-week low of $12.72 and a 52-week high of $34.47.

Institutional Trading of Immunovant

Institutional investors and hedge funds have recently made changes to their positions in the business. Strs Ohio bought a new stake in shares of Immunovant during the first quarter worth $27,000. FNY Investment Advisers LLC purchased a new position in shares of Immunovant during the first quarter valued at $34,000. BI Asset Management Fondsmaeglerselskab A S purchased a new position in shares of Immunovant during the first quarter valued at $37,000. Farther Finance Advisors LLC increased its stake in shares of Immunovant by 142,750.0% during the second quarter. Farther Finance Advisors LLC now owns 2,857 shares of the company’s stock valued at $46,000 after buying an additional 2,855 shares during the period. Finally, Headlands Technologies LLC purchased a new position in shares of Immunovant during the first quarter valued at $51,000. 47.08% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Immunovant

In other news, insider Michael Geffner sold 2,385 shares of Immunovant stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $18.15, for a total transaction of $43,287.75. Following the completion of the sale, the insider directly owned 221,825 shares in the company, valued at approximately $4,026,123.75. This trade represents a 1.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CTO Jay S. Stout sold 2,805 shares of Immunovant stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $18.15, for a total value of $50,910.75. Following the sale, the chief technology officer owned 204,919 shares of the company’s stock, valued at approximately $3,719,279.85. This trade represents a 1.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 7,869 shares of company stock valued at $140,384. Corporate insiders own 1.80% of the company’s stock.

About Immunovant

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.